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1. Introduction
Twenty-three participants from 6 countries (England; Germany; Italy; Sweden, The 
Netherlands; USA) attended the 226th ENMC workshop on Duchenne biomarkers “Towards 
validated and qualified biomarkers for therapy development for Duchenne Muscular 
Dystrophy.” The meeting was a follow-up of the 204th ENMC workshop on Duchenne 
muscular dystrophy biomarkers.
The workshop was organized with the support of Parent Project Muscular Dystrophy 
(PPMD) and Marathon Pharmaceuticals, which provided travel support for participants from 
the US via an unrestricted grant to PPMD in addition to ENMC support. It was attended by 
representatives of academic institutions, industry working in the Duchenne muscular 
dystrophy field and patient representatives.
1.1. Background to the workshop
1.1.1. Biomarkers—Biomarkers are defined as biological, measurable and quantifiable 
indicators of underlying biological processes. Different types of biomarkers can be 
distinguished: diagnostic biomarkers indicate the presence of disease, prognostic biomarkers 
correlate with predicted disease course, and therapeutic biomarkers are designed to predict 
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or measure response to treatment [1]. Therapeutic biomarkers can indicate whether a therapy 
is having an effect. This type of biomarker is called a pharmacodynamics biomarker and can 
be used to e.g. show that a missing protein is restored after a therapy. Safety biomarkers 
assess likelihood, presence, or extent of toxicity as an adverse effect, e.g. through 
monitoring blood markers indicative of liver or kidney damage.
Sometimes biomarkers can also be used as primary endpoints in clinical trials instead of 
functional outcome measures, and these are termed “surrogate endpoints”. In Europe [2,3] 
biomarkers can only be used as surrogate endpoints after going through a rigorous 
regulatory process to officially qualify them for this purpose. Similar pathways exist in the 
US, where the Food and Drug Administration (FDA) also supplies a process for qualification 
of biomarkers for other contexts of use.
1.1.2. Therapy development for Duchenne muscular dystrophy—Duchenne 
muscular dystrophy (DMD) is a severe genetic disorder that leads to progressive muscle 
wasting and loss. Treatment is currently primarily symptomatic, and corticosteroids are used 
to slow down disease progression. Research into potential treatments is ongoing and many 
potential therapies have moved to the clinical trial phase (e.g. 203 trials were listed for DMD 
in clinicaltrials.gov Feb 14 2017, of which 57 are currently recruiting). Notably, ataluren 
(stop codon read through, PTC therapeutics) has received conditional marketing 
authorisation from the European Medicines Agency (EMA) in 2014 and a marketing 
authorisation application for idebenone (antioxidant, Santhera) is pending in Europe. In the 
US, FDA granted accelerated approval to eteplirsen for the treatment of patients with 
eligible mutations (i.e. those where exon 51 skipping can restore the reading frame, to allow 
the production of a Becker muscular dystrophy like dystrophin protein). Emflaza 
(deflazacort) received full approval from FDA in 2017.
Therapy development for DMD is challenging [4]. Briefly, for a drug to be approved it is 
required to show clinical benefit and a positive benefit/risk ratio in a treated group of 
patients compared to a placebo group. Treatments currently in development for DMD aim to 
slow down disease progression. However, because DMD is a progressive disease spanning 
decades, it might be difficult to prove a clinical benefit during short trials. Indeed most 
clinical trials have durations of less than 48 weeks, which may prove too short in order to 
observe clear benefit (e.g. the FDA draft guidance for DMD therapy development suggests 
trials of longer duration (e.g. 96 weeks [5]). Consistent with this, Pfizer and Sarepta are 
currently conducting 96 week trials for an antimyostatin drug and exon skipping 
compounds, respectively. Given the progressive, and age-dependent irreversible loss of 
muscle associated with DMD, time is of the essence and pharmacodynamic biomarkers that 
indicate a more rapid response that correlates with longer term functional improvement 
would accelerate and facilitate therapy development for DMD. These biomarkers need to be 
quantifiable, reproducibly measureable with small coefficients of variance, and be predictive 
of a therapeutic effect in a shorter timeframe than existing outcome measures.
Currently no qualified biomarkers exist for Duchenne muscular dystrophy (DMD). To align 
efforts, an ENMC workshop was organized on this topic and held in January 2014 [5]. This 
workshop was organized by Profs. Alessandra Ferlini, Peter ‘t Hoen, Kevin Flanigan, Hanns 
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Lochmuller, Francesco Muntoni and Elizabeth McNally and discussed DMD biomarker 
discovery, validation and interpretation. Given the rapid progress and scale of ongoing 
research in this area, the organizers and participants recognized the need to continue 
momentum in this area through another workshop.
The aims of this follow-up workshop were
• To discuss dystrophin quantification and skeletal muscle magnetic resonance 
imaging (MRI) as biomarkers to be able to prioritize and align the work that still 
needs to be done towards qualification.
• To compare the biomarkers detected in blood and urine to select the most 
suitable candidates and discuss future tests to confirm their usefulness
• To set up a way for collecting, storing and sharing blood and urine for biomarker 
identification and validation
2. Session 1: Setting the stage
2.1. 1-1 Introducing the 226th ENMC WS
Alexandra Breukel, Managing Director of ENMC, welcomed the participants underlining 
the role of ENMC in promoting research for the neuromuscular community. She encouraged 
applying for ENMC workshops as translational tools to bridge research and clinical 
applications.
Annemieke Aartsma-Rus introduced the aims of the workshop, working towards validated 
and qualified biomarkers for DMD. Indeed, the focus was on translational outputs of 
biomarker research. Following a period of intense discovery, now we need to prioritize 
biomarkers and implement their application in the clinic and clinical trial settings. 
Considering the chronic nature of DMD and the slow response to treatment with novel 
therapies or in clinical trials, biomarkers remain an ideal option to monitor the clinical 
course or outcomes in a shorter timeframe.
Alessandra Ferlini summarized the previous biomarker meeting achievements (204th ENMC 
workshop, held in [6] 2012). The workshop was quite ambitious in terms of deliverables, but 
this richness was encouraged by the EU BIO-NMD grant which supported many of the 
participants. The main deliverables and milestones were: i) sharing of data and setting up 
collaborations on new biomarker projects between Europe and the US; ii) alignment of 
biomarker discovery modalities in Europe and the US; iii) designing the best model for 
biomarker validation in larger cohorts to speed up translation in clinical practice; iv) 
biomarkers prioritization to facilitate the interaction with regulatory authorities.
Although the goals were many, general consensus was achieved especially on the 
identification of mandatory tools such as shared registries and biorepositories, the 
availability of clinical trial study samples, the use of dedicated technologies and platforms, 
often based on -omics approaches, and use of innovative and dedicated bioinformatics. The 
three conclusive breakout sessions (existing biomarkers; defining actions for combination of 
biomarker data in different cohorts and; issues related to the regulatory authorities) provided 
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a list of the technically/clinically validated biomarkers in DMD that could be taken further 
towards a qualification process with the regulators. The consensus was that dystrophin 
protein measurement and muscle quality assessment by MRI could be qualified as 
pharmacodynamic biomarkers, while CK measurement was debated and considered not 
appropriate for DMD monitoring.
Annemieke Aartsma-Rus then presented on interactions with regulators pertaining to DMD 
biomarker development. Regulatory agencies have a process in place to qualify biomarkers 
for a specific purpose (‘context of use’) [2,3]. Multiple interactions coordinated by patient 
organisations, the TREAT-NMD [7] alliance and a cooperation of science and technology 
(COST) Action (BM1207) [8] have taken place between the DMD field (academics, patient 
organisations and industry) and the regulators to discuss the specific challenges of DMD 
therapy development, including biomarkers where the focus thus far mostly has been on 
dystrophin quantification and magnetic resonance imaging (MRI) [4,9].
The first bilaterally educational effort took place in September 2009. It was hosted by EMA 
and served to raise awareness about DMD specific challenges with the regulators and 
regulatory requirements for outcome measures including biomarkers discussed with the 
DMD field [10]. In March, 2013 EMA published a draft guidance document for the clinical 
investigation of medicinal products for the treatment of Duchenne and Becker muscular 
dystrophies [11]. During the public consultation period, the patient community, TREAT-
NMD and COST Action BM1207 organized a forum discussion again involving all 
stakeholders, to discuss the draft document in light of newly collected data. This resulted in 
aligned feedback from the field, which was implemented in the guidance document that was 
published in December 2015 [12]. The document outlines that no biomarkers existed at that 
time that could be used as primary or key secondary endpoint in phase 3 clinical trials. 
Markers of muscle damage, such as plasma creatine kinase levels, are useful for diagnosis, 
but have limitations in the clinical trial setting, since the creatine kinase levels tend to go 
down with age for DMD patients when muscle tissue is lost due to disease progression, and 
its levels are influenced by the degree of muscle activity. Dystrophin quantification is an 
obvious pharmacodynamic biomarker for therapies aiming to restore dystrophin expression. 
However, the guidelines indicate that current methodology to quantify dystrophin has 
debatable robustness and reproducibility especially for extremely low dystrophin levels. As 
such, dystrophin quantification can only be considered as an exploratory pharmacodynamic 
marker [13]. MRI is mentioned as well, and its use as an exploratory or secondary endpoint 
is encouraged to generate additional data.
Parent Project Muscular Dystrophy meanwhile set up a similar stakeholder meeting with 
FDA representatives in December 2013, and was the first patient organisation ever to 
coordinate the drafting of guidelines themselves. This document was submitted to the FDA 
in June 2014 [14]. Based on this document, FDA published draft guidelines a year later [5]. 
Public consultation ended in October 2015, but no final document has yet been published by 
the FDA. As of this workshop, no biomarker has been qualified for DMD in the US. 
Nevertheless, the accelerated approval of eteplirsen by the FDA was based on dystrophin 
quantification by Western blot.
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3. Session 2: Different perspectives on biomarker development and 
qualification
Elizabeth Vroom (United Parent Project Muscular Dystrophy) introduced the patient 
perspective on biomarker development. DMD families hope the development of validated 
biomarkers will help to have shorter and less burdensome trials. Finding a biomarker which 
could ultimately be used as a surrogate endpoint would be very useful. Also it would be 
valuable to be able to test the effect of drugs in a wider range of DMD patients. Currently 
most trials are done in ambulant patients, while the majority of DMD patients are non-
ambulant. Handling and optimal use of samples are a concern to families as well as 
ownership of left-over materials. One of the greatest concerns is the use of biopsies in 
placebo controlled trials. Before samples are taken, families need to know whether 
regulatory agencies have agreed with the proposed methods of analysis. There is a need to 
improve the knowledge about the role and choice of biomarkers in the DMD community.
Ellen Welch (PTC Therapeutics) gave the perspective from industry, underlining the need for 
biomarkers in clinical trials, but also outlining the need for robust and validated assays to 
assess biomarker levels, as was discussed in more detail at the previous ENMC workshop on 
DMD biomarkers [6].
Jane Larkindale (C-Path) presented on the Duchenne Regulatory Science Consortium (D-
RSC), which was set up through a research agreement between Parent Project Muscular 
Dystrophy and the Critical Path Institute (C-Path) to support regulatory qualification of drug 
development tools for DMD to enable the earliest possible patient access to new treatments. 
C-Path has eleven years of experience in regulatory qualification of drug development tools, 
including qualification of multiple biomarkers with the FDA, EMA and the Pharmaceuticals 
and Medical Devices Agency (PMDA, Japan).
Due to muscle damage, serum levels of aspartate transaminase and alanine transaminase, 
AST and ALT, are respectively high in DMD patients. As these are typically used as liver 
safety biomarkers, AST and ALT serum elevation can lead to DMD patients being 
misdiagnosed as having liver damage but also prevents assessment of liver toxicity in drug 
development programs using these markers for DMD patients. A series of preclinical and 
clinical studies have demonstrated that glutamate dehydrogenase (GLDH) is consistently 
low in adults and children of both sexes with and without muscle damage. It consistently 
increases proportionally to liver damage caused in different ways as measured by existing 
biomarkers in both animals and humans. The Predictive Safety Testing Consortium of C-
Path is seeking FDA and EMA qualifications for the biomarker as a measure of liver toxicity 
in patients with underlying muscle damage, and with D-RSC, they will seek in vitro 
diagnostic status for the assay and work with the community to ensure availability to DMD 
patients, and those developing new therapies for the disease.
C-Path’s experience with biomarker qualification shows the importance of determining the 
context of use for biomarkers early in their development, and working with the agencies to 
agree on the level of evidence needed for the specific context. D-RSC has an FDA liaison 
engaged in discussions to ensure this. Levels of evidence for some contexts (e.g. surrogate 
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endpoints) can be very high, while evidence needed to qualify biomarkers for other uses 
(e.g. to define inclusion criteria) may require less data. Initial contexts can be expanded with 
additional data. C-Path is working with the FDA and others to define the evidentiary 
standards required for qualification across all disease areas.
C-Path recognizes the importance of using data standards to build integrated databases to 
support qualification efforts, so as to build scientifically valid databases representing the 
patient population as a whole. It has been found that assay validation and continuity in data 
collection between sites are critical to qualification efforts. Furthermore, it has been found 
that discussion of statistical plans with the authorities early in development of a tool is an 
advantage in assuring that all stakeholders are aligned, and the tools may be acceptable for 
qualification. D-RSC is open to working with others on qualification of additional 
biomarkers.
Pietro Spitali (Leiden University Medical Center) presented the early academic perspective 
on biomarker development and qualification. The presentation focused on molecular 
biomarkers and covered multiple aspects including the study design, differences among 
cohorts, discovery platforms and data analysis. The first point was the definition of the aims 
of the study; if the study aims to identify a diagnostic biomarker it is very important to have 
a sufficient number of cases and controls in the discovery cohort, to study the association in 
different replication cohorts, and to correctly identify the most meaningful controls (e.g. not 
only to study Becker muscular dystrophy (BMD) patients vs. healthy controls but also 
compare to other muscular dystrophies which may be misdiagnosed as BMD).
The cancer field is more advanced in terms of biomarker discovery and clinical use. 
Learning from the initiatives performed by other groups in the cancer field helps to identify 
the pros and cons and better tune studies for rare conditions such as DMD. Predictive 
biomarkers (which enable prediction of response to treatment) have been identified in both 
retrospective [15–18] and prospective [19–21] studies (for more detail we refer the reader to 
a recent review paper [22]). With a retrospective study design it is easier to have access to a 
higher number of samples (and follow-up samples), derived from patients receiving standard 
treatments. However, it is difficult to have homogeneous standards of care between countries 
and even between centres in one country, and to have clinical progression monitored 
homogeneously in the population. In a prospective study design the conditions are more 
controlled and it is easier to standardize sample collection, however these studies are 
normally associated with smaller samples sets.
For the identification of biomarkers, the LUMC uses a mixed strategy where samples are 
collected prospectively in order to collect the same type of clinical information for all 
patients and to standardize sample collection as much as possible. Once a sufficient number 
of samples (and follow-up samples) have been collected and the hypothesis has been 
generated based on the most recent literature, the analyses are performed. During the 
presentation the different types of samples (serum/plasma/PAXgene), tube type (heparin 
lithium or EDTA), sample processing (e.g. clotting time and globin depletion) and analysis 
platforms (e.g. targeted and untargeted proteomics) in relation to the sample types have been 
discussed. It was presented that studies performed in patients affected by different muscular 
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dystrophies using the same study design and proteomic platform result in very different 
output [23,24]. This makes proper powering of studies in different forms of muscular 
dystrophy very challenging.
One key element that was discussed was the need to perform small scale pilot studies in 
order to properly power the actual discovery study and collect independent samples to allow 
multiple layers of validation. Furthermore, there was discussion about the necessity of 
choosing the correct statistical test a priori and of validation of the findings using 
independent reliable, precise and accurate technologies. Finally, collaboration is necessary in 
order to obtain sufficient samples, including samples obtained during clinical trials. These 
samples have value, as they are collected during highly controlled clinical studies.
H. Lee Sweeney (University of Florida) provided the perspective on late stage biomarker 
development from an academic perspective (see next section).
4. Session 3a: Towards biomarker validation and qualification
H. Lee Sweeney reviewed the NIH sponsored Imaging DMD study that is being conducted 
across three sites in the US and is evaluating 150 DMD boys over 5 years. Dixon imaging 
has been found to be more effective than T2 with specific focus on measuring fat fraction of 
key muscle groups. For example, fat fraction of the vastus lateralis muscle is highly 
predictive for loss of ambulation in the near term. Challenges related to MRI in the DMD 
population relate to the limited ability to conduct these studies on very young boys due to 
the need to remain still during imaging.
Volker Straub (University of Newcastle) discussed progress using MRI methods to evaluate 
muscle disease. Imaging has been conducted in LGMD 2I patients (FKRP mutations) 
revealing that muscle which appears fairly impaired can still support ambulation in this 
disorder. He also reviewed the ongoing study of LGMD 2B (dysferlin) patients and the 
specific capacity to distinguish fat from protein and the use of the Myo-MRI website. It was 
highlighted that MRI is a highly useful method that can be adapted to multiple muscle 
groups.
5. Session 3b: Towards biomarker validation and qualification–example of 
dystrophin
Kristy Brown (Solid Biosciences) presented the mass spectrometry based assay developed at 
Children’s National Health System to quantify dystrophin. Details about the procedure 
including gel separation, in gel digestion and mass spectrometry of peptides (endogenous 
and 15 standard peptides) were presented. Dystrophin quantity was calculated as the ratio 
between endogenous and standard peptides for each sample, showing overall low variation 
(CV between 10% and 20%). With the obtained results, Dr. Brown and colleagues applied 
for qualification for dystrophin as a biomarker at the FDA. The procedure started in 2013, 
but it was first put on hold in 2014 by the agency because there was no wide consensus over 
the use of dystrophin as biomarker in the field. When this was resolved in 2015 a new type 
of application was recommended by the FDA, as dystrophin as a surrogate endpoint was 
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deemed too broad. A new letter of intent for dystrophin as a pharmacodynamic biomarker 
was filed in August 2015 and was turned down in 2016, because data were not sufficient to 
initiate full review. At this time the FDA recommended applying for a letter of support, 
which “does not connote qualification of a biomarker and does not endorse a specific 
biomarker test or device. It is meant to enhance the visibility of the biomarker, encourage 
data sharing, and stimulate additional studies” (https://www.fda.gov/drugs/
developmentapprovalprocess/ucm434382.htm). In November 2016, The FDA opted to not 
issue a letter of support to the applicants stating it was unnecessary because eteplirsen 
(Sarepta) was approved based on dystrophin restoration, and as such dystrophin was 
accepted in this application by the FDA as a surrogate endpoint. The overall process 
highlighted the hurdles of biomarker qualification within a defined context of use (e.g. 
dystrophin as surrogate for therapies aiming to restore dystrophin, not for DMD therapies in 
general) while drugs are being evaluated by the agency.
Diane Frank (Sarepta Therapeutics) presented on the dystrophin quantification strategy used 
by Sarepta. This involved the procedure to obtain the muscle biopsy, which has been 
optimized in order to obtain comparable biopsies across study sites. Western blot data 
(currently preferred by the FDA) are obtained by the analysis of 30 micrograms of total 
protein. A 5 point standard curve (0.25%, 0.5%, 1%, 2%, and 4% of healthy control) is used 
to interpolate the data. Equal amounts of protein amounts are loaded for all samples and a 
defined film exposure is used to avoid signal saturation. Quality checks for a successful 
experiment include a standard curve with R2 above 0.9 and the dystrophin intensity of DMD 
control samples below the intensity of the standard at 0.25%. Specific criteria are in place to 
evaluate whether a gel has sufficient quality to warrant downstream analysis. Alpha-actinin 
is used as a loading control even though this may cause dystrophin underestimation given 
that alpha-actinin is not a sarcolemmal protein and may not appropriately correct for the 
amount of sarcolemma present in that biopsy (which may be considered as the ability of that 
specific piece of muscle to produce dystrophin). It was discussed that dysferlin and spectrin 
might be good loading controls and work is ongoing to test these options.
Western blot data were also compared to data obtained by immunofluorescent analysis of 
dystrophin showing linearity between the 2 measurements across healthy controls, BMD and 
DMD patients. Even though the percentage of dystrophin positive fibres was perceived as 
subjective by the FDA, improvements are possible by automating the analysis after finding a 
shared consensus over the minimum requirements for dystrophin positivity.
Eric Hoffman (Reveragen Biopharma, AGADA Biosciences) presented assays available at 
AGADA Biosciences to quantify dystrophin. AGADA Biosciences is performing the 
dystrophin quantification in samples obtained in interventional clinical trials with antisense 
oligonucleotides (e.g. Nippon Shinyaku trial targeting exon 53). They provide video tutorials 
on how the procedure has to be performed and if that is not sufficient, support on site is 
available to show each step of the protocol to ensure high method reproducibility across 
sites. They optimized each step of the protocol starting with the muscle biopsy processing 
until data acquisition. Protocol instructions include tips on the freezing procedure, 
solubilization method and loading controls (multiple tested such as vinculin, alpha-actinin, 
spectrin and myosin heavy chain). The method includes details about accuracy, precision, 
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specificity, linearity, limit of detection, limit of quantification and stability. Dr. Hoffman 
reported dystrophin levels to be stable in frozen biopsies for 1–2 years at least.
AGADA Biosciences is not only providing western blot as a dystrophin assay but also other 
quantitative assays such as mass spectrometry which is less sensitive due to the absence of 
signal amplification, but it is characterized by low variation coefficient lying within the FDA 
guidelines. They also provide other services such as immunostaining and exon skipping 
quantification. All methods have standard operating procedures to be precisely followed.
Francesco Muntoni (University College London) presented the next steps to take in the 
collaborative effort of harmonizing dystrophin quantification. Different technologies to 
detect dystrophin in muscle biopsies are available. FDA prefers western blot information 
over the percentage of dystrophin positive fibres, or dystrophin intensity on 
immunocytochemistry, as they perceive the latter assays as more subjective. Efforts are 
however ongoing on methodology to quantify the dystrophin levels in individual muscle 
fibres using automated, unbiased techniques. This would provide reliable data if the 
technique is performed in an automated way, which is at the moment being tested in 
different labs (e.g. BioCruces Health Research Institute in Spain; Flagship Biosciences; 
Dubowitz Centre London) for DMD, BMD and intermediate phenotypes. It is challenging to 
have references of ‘normal dystrophin levels’ since there is variation in dystrophin 
expression between fibres within a muscle and between fibres of different muscles in healthy 
individuals.
Western blot data were presented in detail including a discussion of which loading marker 
would be more appropriate and vinculin was suggested as a good candidate as it is stable and 
not differentially expressed in dystrophic muscles compared to healthy controls. Finally, the 
data of a Cooperation of Science and Technology (COST) Action funded working group 
aiming to compare exon skipping quantification with different techniques across different 
European labs were presented (COST Action BM1207, manuscript in preparation).
Ellen Welch (PTC Therapeutics) discussed the nonsense read-through approach to treat 
patients carrying nonsense mutations. It was shown that premature stop codons are often the 
result of mutations of arginine encoding triplets into nonsense codons and that, often read-
through of the stop codon reintroduced arginine in the correct position. The results of the 
phase 2a open label dose ranging study and the phase 2b study with ataluren were presented. 
In the phase 2a study boys were treated 3 times a day due to the short half-life of the 
compound and participants were divided into 3 groups: 6 boys were treated with 4-4–8 
mg/kg, 20 boys with 10-10–20 mg/kg and 12 boys with 20-20–40 mg/kg daily. The 
treatment duration was 28 days, boys were 5 to 17 years of age, 4 were non-ambulatory and 
11 were not treated with corticosteroids. Mutations were spread throughout the coding 
sequence. The change in dystrophin expression was presented as a percentage increase and 
seemed to follow a normal distribution with some patients showing an increase in dystrophin 
while others showed a decrease. There were no remarkable differences among the treatment 
groups. The phase 2b study was divided into 2 dose groups including 20 boys on 10-10–20 
mg/kg and 12 boys on 20-20–40 mg/kg. Treatment duration was 48 weeks; the age range 
was 6–16 years of age and all 3 stop codons were represented in the study groups. Cultured 
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myotubes were obtained and treatment with ataluren showed dystrophin staining for all 
subjects.
6. Session 4a: Candidate biomarkers–results in DMD and BMD (serum)
Jessica Chadwick (SomaLogic) reviewed the proprietary aptamer technology used by 
SomaLogic. Currently, 1300 proteins per sample are quantified in a multiplex setting. Newer 
assays are anticipated to allow quantification of >3600 proteins per sample. A previous 
study using the smaller platform identified 44 proteins that differed between DMD and 
control serum [23]. The newer platform extends this finding to 163 proteins, including 
confirmation of the prior 44. The current list expands into proteins implicated in muscle 
development, metabolism, and mitochondrial function. Interestingly, immune and 
inflammatory proteins were reduced. The cohort in this study included both those treated 
with steroids as well as those not on steroids. A new DMD cohort is planned to evaluate how 
these components change over time in DMD, and a consortium is being developed to carry 
out this analysis.
Pietro Spitali discussed using the Somascan aptamer-based method to profile serum from 15 
DMD subjects and 9 healthy controls. Of the DMD subjects, 11 were ambulant and all but 
one had been treated with steroids. With this aptamer approach, 111 proteins were decreased 
in DMD serum while 148 proteins were increased. A number of these proteins (n = 32) were 
shared among other DMD serum profiling studies [23]. Furthermore, the same aptamer 
method was also used to study 14 patients who were followed for an average of 4 years. 
More than 400 proteins were observed to change over time. Metabolic profiling of a distinct 
DMD cohort (30 DMD and 10 controls, all fasted) identified 9 markers that differed between 
the two groups. A lipidomics analysis in 30 DMD patients identified two lipids that were 
altered including one that may correlate with performance on the North Star assessment tool.
Eric Hoffman discussed plans for vamorolone, a novel dissociative steroid selected for its 
ability to bind the glucocorticoid receptor (GR) with high affinity but not to dimerize the 
receptor [25,26]. The Phase IIA study is recruiting 48 DMD boys and Phase IIB is 
anticipated to start in the coming year. Dr. Hoffman discussed the challenges of assessing the 
effect of vamorolone on NF-κB since the standard assays monitor activity after 
lipopolysaccharides (LPS), an especially strong stimulus, which may not adequately reflect 
what occurs in DMD. At very high doses, adrenal suppression may occur with vamorolone. 
A proteomic scan was conducted on DMD and inflammatory bowel disease patients using 
aptamer technology to identify pharmacodynamic markers of glucocorticoid use [27]. This 
study identified MMP3, leptin, insulin, afamin and GH binding protein.
Christina Al-Khalili Szigyarto (KTH Royal Institute of Technology) reviewed the use of the 
Luminex platform which is used to assess protein content. She described the human protein 
atlas (http://www.proteinatlas.org) and the project to generate antibodies to all human 
proteins to more than 50,000 antigens. This website offers information where tissue specific, 
including muscle specific, proteins can be discerned. Protein biomarkers for muscular 
dystrophy were discussed including enolase 3 and carbonic anhydrase 3 (CA3) (which were 
also detected with the Somalogic’s assay), confirming the utility of the method [23,24,28]. 
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With this approach, antibody specificity for the target of interest is critical. Paired 
antibodies, where two or more antibodies target different regions of the same target protein, 
are highly useful to improve the robust, specific and quantitative nature of the findings. A 
new biomarker, nestin A, was discussed and the need for longitudinal studies was reinforced.
Graham McClorey (Oxford) is working within the group of Matthew Wood and focused on 
identifying serum micro RNA (mIR) biomarkers for DMD using animal models like the mdx 
mouse. mIR-1, 133 and 206 all decrease in early postnatal life in the mouse with an increase 
at 3–4 weeks of age [29]. Studies are being conducted using downhill running in order to 
determine the effect of acute exercise. Most mIRs increase immediately and then again at 
day 7. A newer study is now focused on sequencing small RNAs from mdx mice. mIR-483P 
was identified and is upregulated in DMD patients from the Newcastle Biobank.
An aptamer based serum study in mdx mice (1129 aptamers assayed) identified 75 proteins 
that were increased and 26 that were decreased in mdx mice. Among these ADAMTS5 was 
studied in patients with DMD, BMD, and FSHD; a positive association with age was found 
for DMD and FSHD while in BMD patients there was a negative correlation with age.
Jon Tinsley (Summit plc) described a larger aptamer analysis using the system with the 
capacity to detect nearly 4000 proteins in the serum. In this study, six DMD patients with 3–
4 serum samples collected over 3 months were used. Serum levels varied up to 50% over 
several weeks for many of the target proteins. Carbonic anhydrase 3 (CA3) and CK showed 
the least variability among the samples, but these protein biomarkers were still felt to be 
highly variable. mIR-133a and mIR-133b were both up in early DMD. Given Summit plc’s 
interest in upregulation of utrophin, Dr. Tinsley presented data on their approaches to 
accurately quantify utrophin upregulation in muscle biopsies from treated DMD patients.
7. Session 4b: Candidate biomarkers–results in DMD and BMD (urine)
Pietro Spitali discussed the utility of examining urine biomarkers in mdx mice. Urine is an 
attractive source since it is noninvasive to collect. PGDM (11,15-dioxo-9α-hydroxy-,2,3,4,5- 
tetranorprostan-1,20-dioic acid (tetranor PGDM)) was shown to be elevated in DMD 
patients compared to healthy controls, especially for patients above 9 years of age [30]. 
Metabolic profiling of urine is ongoing in mdx mice. Prednisone was detected in the urine in 
steroid-treated DMD patients and mdx mice, providing a useful internal control. Issues 
surrounding urine biomarkers include variability in urine volume and the need to provide 
normalization.
Francesco Muntoni presented miRNAs as biomarkers in urine, since miRNAs have been 
studied by multiple groups in serum samples from animal models of muscle disease and 
DMD patients [31–36]. He also reviewed the challenges of profiling miRNAs from urine 
samples and the variability introduced by ambulatory status and activity as well as treatment 
status with respect to corticosteroids. He presented data acquired from 7 healthy controls 
and 30 DMD patients (18 ambulant and 12 non-ambulant). All miRNAs (178) were 
quantified with a TaqMan RT-PCR approach, and all miRNAs could be detected in the urine 
of healthy controls. miRNAs were identified that were differentially expressed between 
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healthy and DMD, while others were associated with either prednisone or deflazacort 
treatment.
Alessandra Ferlini (University of Ferrara) showed the use of urine-derived cells to generate 
cellular models of DMD [37]. Urine cells can be readily obtained and directly 
reprogrammed using MyoD. These cellular models are highly useful for testing antisense 
oligonucleotides for their ability to induce in frame production of dystrophin. As exon 
skipping moves to testing for rare DMD mutations, having a readily accessible cell model 
will be highly useful to e.g. study dystrophin restoration in vitro.
Elizabeth McNally (Northwestern University) also discussed the ease of working with urine-
derived cells and their application to testing exon skipping. She reviewed progress in 
developing exon skipping to treat Limb Girdle Muscular Dystrophy type 2C, which is due to 
loss of function mutations in SGCG, encoding γ-sarcoglycan. In order to treat 
approximately half of the LGMD 2C patients, a uniform approach is planned that 
necessitates skipping exons 4, 5, 6 and 7. This would leave exons 2, 3 and 8 encoding a 
protein, referred to as Mini-Gamma. In order to assess whether Mini-Gamma is viable as a 
strategy, transgenes were created to test Mini-Gamma expression in both Drosophila and 
mouse models of LGMD 2C [38]. It was shown that transgenic expression of Mini-Gamma 
rescued many distinct features of muscular dystrophy. In order to test exon skipping in 
LGMD 2C, fibroblasts and urine cells were reprogrammed into myogenic lineages using 
MyoD to establish a cell based model of LGMD 2C [39]. Exon skipping was demonstrated 
in these models [38]. Furthermore, she showed that urine derived cells can be gene edited 
using CRISPR/Cas9 methods.
8. Session 4c: Genetic modifiers in DMD
Luca Bello (University of Padova) discussed the rs28357094 genetic variant present in the 
promoter of the SPP1 gene, which has been linked to age of ambulation loss in DMD [40–
42]. The SPP1 gene encodes the protein osteopontin and is elevated after muscle injury and 
during regeneration. It was recently reported that the SNP exerts its function when patients 
are treated with corticosteroids [43]. In order to understand the mechanism underlying the 
SNP effect in the presence of corticosteroids, myoblasts of 11 DMD patients and 9 healthy 
controls were cultured with and without deflazacort to study the response of the SPP1 
promoter to corticosteroids. Gene expression and protein levels were used as promoter 
activity readouts. No change was detected in gene expression or protein levels from DMD 
and healthy control-derived myoblasts. An increase in gene expression of SPP1 was 
observed in DMD myotubes but no difference was recorded at the protein level. Two main 
osteopontin protein isoforms were observed, 50 and 55 KDa, and these forms were 
differentially expressed in DMD in response to steroids [44]. Although a comprehensive 
mechanism is still needed to explain how this SNP regulates SPP1/osteopontin expression in 
DMD, it is clear that patients with the TT genotype respond better to corticosteroid therapy 
compared to patients carrying other genotypes.
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9. Session 5: Sample and data sharing
The final session was on ways to facilitate sample and data sharing for biomarker discovery 
and validation. Several best practices were shared. First, Luca Bello outlined how 
identification and validation of genetic modifiers for DMD, such as variations in SPP1 and 
LTBP4, benefited from an international collaboration. With rare diseases there are 
challenges to validate genetic modifiers. Generally, cohorts are small, and there are many 
confounders, such as steroid use, variation in care standards and ancestry. Currently there are 
two large cohorts available for modifier identification: the CINRG cohort and the Bio-NMD 
cohort. Through a reciprocal agreement modifiers identified in one cohort are validated in 
the other. Most recently this was used to validate a SNP in CD40 [45].
For MRI protocol development, there is a good cross talk between US and European 
initiatives, as was presented by Lee Sweeney and Volker Straub. In fact, the MRI work is 
becoming a global effort with common quality assurance protocols and standard operating 
procedures. Furthermore, using central data analysis, it has been confirmed that data 
collection and interpretation is reliable at different sites and over time. There is consensus on 
what to qualify as a biomarker with the regulators (fat fraction as measured by Dixon).
Pietro Spitali presented on an effort that was initiated after the 204th ENMC workshop to 
make an inventory of serum and plasma samples available for biomarker validation studies. 
The work was sponsored by a small grant from Duchenne Parent Project Netherlands. 
Samples have been identified, some of which are linked to functional data and some of 
which are longitudinal. It is clear that more effort is needed to collect additional samples and 
functional data in a controlled way. Samples collected in placebo arms of clinical trials 
would be ideal to validate candidate biomarkers.
Eric Hoffman presented from an industry perspective biomarker discovery in clinical trial 
samples that potentially poses a risk, because all drug related data is reportable and 
discoverable. In particular, unexpected findings in treatment arms may be difficult to 
interpret as to whether they are a safety concern. However, using a data analysis plan which 
outlines which part of the data will be analysed, unexpected findings may be avoided.
Eric Hoffman further presented on the issue of data comparability and the need for reference 
samples. Ideally datasets should become available after publication as a public resource. 
However, hosting and curating these datasets is laborious and expensive.
The topic of biobanking was then discussed during breakout sessions focusing on setting up, 
using and maintaining a virtual biobank of samples to be used to validate candidate 
biomarkers. First there was consensus on criteria that new therapeutic candidate biomarkers 
need to fulfil: they need to be specific, reproducible, reliable and robust. Ideally, markers 
found in animal models should be confirmed in humans, markers need to be responsive to 
treatment in animal models and need to be measurable in easily accessed samples (e.g. 
blood, urine, saliva).
The group agreed that a virtual biobank is needed, with a central management system and a 
central catalogue. This can make use of existing format such as Eurobiobank 
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(www.eurobiobank.eu) and BB-MRI (biobanking and biomolecular research infrastructure). 
These are European initiatives, and would have to be set up on a more global scope for the 
DMD biobank. Standardized protocols for obtaining and collecting samples and informed 
consent are available at Eurobiobank and RD-Connect and should be used. Since for 
regulatory qualification the link to functionality is required, it will be crucial to also collect 
an agreed upon set of functional data in a standardized manner.
The group agreed that an oversight committee is required for custodianship of these samples. 
This committee should have representatives from patient advocacy groups, academia and 
industry, and should have access to a larger extended group when expertise is required for 
evaluations of requests.
Requests should be evaluated for several criteria, based on the model used by Telethon Italy. 
Both academic and industry groups would have access to the samples, provided they adhere 
to the selection criteria, which include items like the amount of sample (scaled to the 
proposed aims of the research), preliminary data (including information on the limit of 
detection and fold change of the biomarker(s)). Finally, risk assessment is included, where 
applicants have to show they have funding to achieve their aims, outline timelines and power 
calculations. Therapeutic biomarkers would be prioritized for DMD. There would be a 
publication obligation for everyone who uses samples from the biobank, including when 
results are negative and an obligation to share the results with the community in a timely 
fashion following the RD-Connect model.
Ideally the management part of this virtual biobank should be funded by patient 
organisations and industry. The patient representatives indicated that the patient community 
has played a large role in this thus far and will keep doing this. They also indicated that 
communication and feedback are important, e.g. the metrics of the biobank should be 
reported to the patients regularly.
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